Johnson & Johnson (NYSE:JNJ) today confirmed the appointment of several senior leaders to its executive committee.
New Brunswick, New Jersey-based Johnson & Johnson’s executive committee appointments follow the previously announced transition of the CEO position from Alex Gorsky — who will serve as Executive Chairman — to Vice Chair of the Executive Committee, Joaquin Duato, which will become effective Jan. 3, 2022.
From the effective date, all members of the executive committee will report to Duato. In addition to the appointments, Johnson & Johnson said in a news release that Michael Sneed, EVP of Global Corporate Affairs & Chief Communication Officer, will retire on April 1, 2022.
Here are Johnson & Johnson’s new executive committee appointments:
- Chairman of Global Commercial Strategy Organization, Vanessa Broadhurst, was appointed EVP of Global Corporate Affairs.
- Global Head of External Innovation Dr. Bill Hait was appointed EVP, Chief External Innovation, Medical Safety & Global Public Health Officer.
- Janssen Pharmaceutical Companies (of Johnson & Johnson) Global Head of R&D Dr. Mathai Mammen was appointed EVP, Pharmaceuticals, R&D.
- Chief Information Officer James Swanson was appointed EVP, Chief Information Officer.
“I am thrilled to appoint this group of dynamic and experienced leaders to Johnson & Johnson’s executive committee,” Duato said in the release. “Each represents a high level of dedication to our mission, as well as proven track records of strategic thinking, strong execution, and credo-based leadership. As a whole, they are representative of the deep bench of talent we see at every level of our organization, as well as the tremendous opportunity ahead for Johnson & Johnson as we enter a new and exciting chapter.”